Literature DB >> 8138259

Serum hepatitis C virus RNA quantity and histological features of hepatitis C virus carriers with persistently normal ALT levels.

M Naito1, N Hayashi, H Hagiwara, N Hiramatsu, A Kasahara, H Fusamoto, T Kamada.   

Abstract

We studied hepatitis C virus carriers with normal liver function to evaluate the histological features of their livers and the replicative levels of hepatitis C virus. Liver biopsies were performed in 22 hepatitis C virus carriers with persistently normal ALT levels. Hepatitis C virus RNA in serum was quantified with a competitive assay that combined reverse transcription and the polymerase chain reaction, which is based on co-amplification of the target RNA with known amounts of synthetic mutated RNA. Three patients had normal livers on histological study, whereas the other 19 had chronic persistent hepatitis, with lymphoid infiltrates or aggregates in portal tracts commonly observed but intralobular inflammatory changes absent or minimal. The titer of hepatitis C virus RNA (logarithmic transformed copy number per milliliter of serum) varied from 4.0 to 8.0 (mean +/- S.D.: 6.3 +/- 1.1); it was significantly lower in the three patients with normal livers (4.3 +/- 0.2) than in those with chronic persistent hepatitis with mild (6.4 +/- 0.8, n = 11) or moderate (7.1 +/- 0.5, n = 8) portal inflammation. The titer of hepatitis C virus RNA was correlated with the total score (r = 0.68) and the score for portal inflammation (r = 0.68) in the histological activity index. These results indicated that there seem to be "healthy carriers" of hepatitis C virus with extremely low levels of viral replication. However, in most hepatitis C virus carriers with persistently normal ALT levels, there are inflammatory changes in the portal tracts, with severity depending on the replicative levels of hepatitis C virus.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8138259

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  22 in total

1.  Effect of human immunodeficiency virus infection on hepatitis C virus infection in hemophiliacs.

Authors:  M G Ghany; C Leissinger; R Lagier; R Sanchez-Pescador; A S Lok
Journal:  Dig Dis Sci       Date:  1996-06       Impact factor: 3.199

Review 2.  Hepatitis C: diagnosis and treatment.

Authors:  I Scotiniotis; C A Brass; P F Malet
Journal:  J Gen Intern Med       Date:  1995-05       Impact factor: 5.128

3.  Comparison of two quantitative hepatitis C virus reverse transcriptase PCR assays.

Authors:  W K Roth; J H Lee; B Rüster; S Zeuzem
Journal:  J Clin Microbiol       Date:  1996-02       Impact factor: 5.948

4.  Prevalence of hepatitis C virus genotypes in southern Italy.

Authors:  S Cicciarello; G Borgia; J Crowell; R Ciampi; R Cerini; R Orlando; M Mainolfi; L Reynaud; M Milano; M Piazza
Journal:  Eur J Epidemiol       Date:  1997-01       Impact factor: 8.082

5.  Nucleotide and amino acid complexity of hepatitis C virus quasispecies in serum and liver.

Authors:  B Cabot; M Martell; J I Esteban; S Sauleda; T Otero; R Esteban; J Guàrdia; J Gómez
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

6.  Histological damage in chronic hepatitis C is not related to the extent of infection in the liver.

Authors:  E Rodríguez-Iñigo; J Bartolomé; S de Lucas; F Manzarbeitia; M Pardo; C Arocena; J Gosálvez; H Oliva; V Carreño
Journal:  Am J Pathol       Date:  1999-06       Impact factor: 4.307

7.  Histological features and HLA class II alleles in hepatitis C virus chronically infected patients with persistently normal alanine aminotransferase levels.

Authors:  C Renou; P Halfon; S Pol; P Cacoub; E Jouve; J P Bronowicki; J P Arpurt; H Rifflet; M Picon; X Causse; V Canva; J Denis; A Tran; M Bourliére; D Ouzan; A Pariente; S Dantin; L Alric; V Cartier; M Reville; S Caillat-Zucman
Journal:  Gut       Date:  2002-10       Impact factor: 23.059

8.  Serum levels of soluble interleukin-2 receptors and effects of interferon-alpha for patients with chronic hepatitis C virus.

Authors:  J Hayashi; Y Kishihara; K Yamaji; E Yoshimura; M Ohmiya; Y Tani; H Ikematsu; S Kashiwagi
Journal:  Dig Dis Sci       Date:  1995-08       Impact factor: 3.199

9.  Outcomes of interferon alpha and ribavirin treatment for chronic hepatitis C in patients with normal serum aminotransaminases.

Authors:  C-K Hui; A Monto; T Belaye; E Lau; T L Wright
Journal:  Gut       Date:  2003-11       Impact factor: 23.059

10.  Serum and liver HCV RNA levels in patients with chronic hepatitis C: correlation with clinical and histological features.

Authors:  L De Moliner; P Pontisso; G L De Salvo; L Cavalletto; L Chemello; A Alberti
Journal:  Gut       Date:  1998-06       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.